REGENXBIO REPORTS STRONG 18-MONTH DURABILITY FOR RGX-202 AND FLAGS 2026 AS A KEY YEAR WITH MAJOR DATA READOUTS AND AN FDA PDUFA DECISION AHEAD. || THE COMPANY ALSO EXPECTS A $100 MILLION PAYMENT FROM ABBVIE IN THE FIRST HALF OF 2026, STRENGTHENING ITS CASH POSITION.